Investigational Drug Information for VTP-194204
✉ Email this page to a colleague
What is the development status for investigational drug VTP-194204?
VTP-194204 is an investigational drug.
There have been 18 clinical trials for VTP-194204.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 21st 2019.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Psoriasis, and Eczema. The leading clinical trial sponsors are Steba Biotech S.A., Vitae Pharmaceuticals, Inc., and STEBA France.
There are one hundred and fourteen US patents protecting this investigational drug and one international patent.
Summary for VTP-194204
| US Patents | 114 |
| International Patents | 1,295 |
| US Patent Applications | 253 |
| WIPO Patent Applications | 99 |
| Japanese Patent Applications | 105 |
| Clinical Trial Progress | Phase 3 (2019-01-21) |
| Vendors | 15 |
Recent Clinical Trials for VTP-194204
| Title | Sponsor | Phase |
|---|---|---|
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | ICON plc | Phase 3 |
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | Medpace, Inc. | Phase 3 |
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | PrimeVigilance | Phase 3 |
Clinical Trial Summary for VTP-194204
Top disease conditions for VTP-194204
Top clinical trial sponsors for VTP-194204
US Patents for VTP-194204
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| VTP-194204 | See Plans and Pricing | Autoimmune disorder treatment using RXR agonists | lo Therapeutics, Inc. (Santa Ana, CA) | See Plans and Pricing |
| VTP-194204 | See Plans and Pricing | Treatment of cancer with specific RXR agonists | Io Therapeutics, Inc. (Santa Ana, CA) | See Plans and Pricing |
| VTP-194204 | See Plans and Pricing | DISC-1 pathway activators in the control of neurogenesis | Massachusetts Institute of Technology (Cambridge, MA) The General Hospital Corporation (Boston, MA) | See Plans and Pricing |
| VTP-194204 | See Plans and Pricing | Treatment of cancer with specific RXR agonists | IO Therapeutics, Inc. (Santa Ana, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for VTP-194204
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| VTP-194204 | Australia | AU2012352149 | 2031-12-13 | See Plans and Pricing |
| VTP-194204 | Australia | AU2017210644 | 2031-12-13 | See Plans and Pricing |
| VTP-194204 | Canada | CA2858882 | 2031-12-13 | See Plans and Pricing |
| VTP-194204 | China | CN104114171 | 2031-12-13 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
